Archive for September, 2009

Joseph Giuffrida, PHD Appointed To CleveMed Vice President, General Manager

Wednesday, September 9th, 2009

Cleveland, Ohio (September 9, 2009) - Cleveland Medical Devices Inc. (CleveMed) has announced the promotion of Joseph P. Giuffrida, PhD to Vice President, General Manager of the Division of Movement Disorders. As CleveMed continues to expand as a medical device company, Dr. Giuffrida will continue filling a crucial role to assist with the company’s continued growth.

Dr. Giuffrida, 33, completed his BS, MS and PhD in Biomedical Engineering at Case Western Reserve University with a concentration in rehabilitation engineering. He began his career at CleveMed in 2000 as an Applications Engineer and upon receipt of his PhD in 2004, became a Principal Investigator and eventually Director of the Division of Movement Disorders. Within these roles, Dr. Giuffrida has secured over $8 million in funding from both the National Institutes of Health and the State of Ohio to fuel the research, development, and commercialization of innovative medical devices focused on aiding in the diagnosis and therapy of movement disorders. He has secured FDA clearance to market for a number of CleveMed systems, managed reimbursement strategies for new and emerging technology, established multiple world renowned key opinion leaders and clinical consultants, and lead the marketing and sales teams for CleveMed’s clinical movement disorder products as well as the research and educationproduct lines.

Most notably, CleveMed’s Division of Movement Disorders commercialized and launched Kinesia under Dr. Giuffrida’s direction. This technology is intended to provide a standardized platform for objectively quantifying motor symptoms associated with Parkinson’s disease. Additional research and development in this Division is focused on extending the market applications for Kinesia from clinical office visits to home monitoring and deep brain stimulation programming, assistive technologies to aid in communication for persons with limited mobility and speech impairment and the development of rehabilitation systems to aid in motor recovery after brain injuries such as stroke or cerebral palsy.

In addition to the Division of Movement Disorders, Dr. Giuffrida also manages CleveMed’s line of products focused on the research and education market. Dr. Giuffrida was able to commercialize CleveMed’s wireless physiological monitoring technology into specific academic and university based target applications to increase CleveMed’s sales both domestically and internationally.

“Joe has been a crucial part of our success and we are thrilled to promote him to this vital position” said Hani Kayyali, President. “He will continue to grow our role as a pioneer in the area of Parkinson’s disease monitoring and movement disorders research to new levels”.

About CleveMed

CleveMed was founded with the goal of developing innovative telemetry devices for a variety of medical applications. Today, CleveMed is developing and pioneering the use of novel wireless monitoring systems for high growth neurology and rehabilitation applications, including movement disorders and sleep disorders. Through these innovations, CleveMed has developed a growing range of products that address the needs of the medicalresearch and academic communities. For more information, please visitwww.clevemed.com

For More Information Contact:

Maureen Phillips
Cleveland Medical Devices Inc.
P: 216.791.6720
mphillips@clevemed.com
www.clevemed.com

DreamPort ushers in
concept of attended PSG Anywhere

Thursday, September 3rd, 2009

CleveMed’s DreamPort, expands the reach of your sleep business by allowing remotely attended sleep studies to be done from anywhere, using a bedside system controlled by sleep technologists miles away – over the internet. Broadband technology combined with a camera is used to transmit the patient data and video in real-time, allowing studies to be conducted anywhere the patient is.

  • DreamPort is particularly ideal for those who are unable or reluctant to make it into the sleep lab, such as pediatric patients, cross country truckers, the elderly, those suffering from chronic pain and hospital inpatients.
  • In addition, this system gives clinicians and researchers greater flexibility to conduct sleep studies anywhere. DreamPort is suitable for clinical trials as it allows for cost effective research studies to be conducted in the patient’s home while adding an additional element of home care.
  • DreamPort combines the comfort and cost-effectiveness of home testing with the peace of mind of an attended study.
  • Dr. Golish, is a board-certified specialist in sleep medicine and author of more than 300 publications on sleep. He is a member of the Sleep Steering Committee for the ACCP. After 35 years as a professor in The Cleveland Clinic and Co-Director of Sleep Medicine, he has left academic medicine to advance a new paradigm in sleep medicine, focusing on accessibility and affordability. His goals are the proper use of HST and fostering continuity of care, in an efficient and cost-effective manner, while preserving high quality. He is currently the Medical Director of Cleveland Medical Devices (CleveMed) and Director of Sleep Center, North Coast Clinical Trials, in Cleveland, Ohio.